FAMSi: A Synthetic Biology Approach to the Fast Assembly of Multiplex siRNAs for Silencing Gene Expression in Mammalian Cells

Fang He,1,2,3 Na Ni,2,3 Zongyue Zeng,1,2 Di Wu,1,2 Yixiao Feng,2,3 Alexander J. Li,2 Benjamin Luu,2 Alissa F. Li,2 Kevin Qin,2 Eric Wang,2 Xi Wang,1,2 Xiaoxing Wu,2,3 Huaxiu Luo,2,4 Jing Zhang,2,3 Meng Zhang,2,5 Yukun Mao,2,6 Mikhail Pakvasa,2 William Wagstaff,2 Yongtao Zhang,2,7 Changchun Niu,2,8 Hao Wang,1,2 Linjuan Huang,2,3 Deyao Shi,2,9 Qing Liu,2,10 Xia Zhao,2,7 Kai Fu,2,6 Russell R. Reid,2,11 Jennifer Moriatis Wolf,2 Michael J. Lee,2 Kelly Hynes,2 Jason Strelzow,2 Mostafa El Dafrawy,2 Hua Gan,1 Tong-Chuan He,2 and Jiaming Fan1

INTRODUCTION

RNA interference (RNAi) is mediated by an ~21-nucleotide double-stranded small interfering RNA (siRNA) and shows great promise in delineating gene functions and in developing therapeutics for human diseases. However, effective gene silencing usually requires the delivery of multiple siRNAs for a given gene, which is often technically challenging and time-consuming. In this study, by exploiting the type II restriction endonuclease-based synthetic biology methodology, we developed the fast assembly of multiplex siRNAs (FAMSi) system. In our proof-of-concept experiments, we demonstrated that multiple fragments containing three, four, or five siRNA sites targeting common Smad4 and/or BMPR-specific Smad1, Smad5, and Smad8 required for BMP9 signaling could be assembled efficiently. The constructed multiplex siRNAs effectively knocked down the expression of Smad4 and/or Smad1, Smad5, and Smad8 in mesenchymal stem cells (MSCs), and they inhibited all aspects of BMP9-induced osteogenic differentiation in bone marrow MSCs (BMSCs), including decreased expression of osteogenic regulators/markers, reduced osteogenic marker alkaline phosphatase (ALP) activity, and diminished in vitro matrix mineralization and in vivo ectopic bone formation. Collectively, we demonstrate that the engineered FAMSi system provides a fast-track platform for assembling multiplexed siRNAs in a single vector, and thus it may be a valuable tool to study gene functions or to develop novel siRNA-based therapeutics.

Received 18 June 2020; accepted 7 October 2020; https://doi.org/10.1016/j.omtn.2020.10.007.

Correspondence: Tong-Chuan He, MD, PhD, Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC3079, Chicago, IL 60637, USA.
E-mail: lche@uchicago.edu

Correspondence: Jiaming Fan, MD, PhD, Ministry of Education Key Laboratory of Diagnostic Medicine, School of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China.
E-mail: fanjiaming1988@cqmu.edu.cn

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
polynephropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.3,5,8–11

In practice, RNAi is usually accomplished either by transfecting chemically synthesized siRNAs into cells, or by expressing short hairpin RNAs (shRNAs) or siRNAs in cells.10–14 Unfortunately, effective RNAi silencing frequently requires multiple siRNAs for a given gene, which is time-consuming to build multiple siRNA expression constructs. To simplify this technical process, we previously developed the pSOS system, in which a single siRNA is produced from the converging U6 and H1 promoters.16 To improve the construction efficiency, we explored the use of the Gibson DNA assembly technique and developed a one-step system (i.e., pSOK) to express multiple siRNA sites in a single vector.17 While the pSOK system has been successfully used for numerous siRNA-based studies,18–25 the Gibson Assembly technique is highly empirical and finicky, rendering it not user-friendly for the researchers with limited experience in molecular cloning. To overcome such practical and technical challenges, we have recently developed a two-step BstXI-based shotgun cloning (BSG) system, consisting of multiple entry vectors with siRNA expression units (SiEU) flanked with distinct BstXI sites, and a retroviral destination vector for shotgun SiEU assembly.26 While functional, the BSG system requires two-stage cloning and more entry vectors if more siRNAs are desired. Thus, a more simplistic and user-friendly system is warranted for the rapid assembly of multiplexed siRNAs in mammalian cells.

For the past decade, synthetic biology has revolutionized genome biology and offers unique approaches for creating new biological systems or redesigning existing ones for new purposes through the use of different techniques to assemble genetic fragments.27 One such technique is to use the type IIS restriction enzyme-dependent DNA assembly methods for rapid construction of large genetic fragments through ordering multi-fragment assembly dictated by the ligation of Watson-Crick base-paired overhangs.28 The type IIS restriction enzymes, such as BsaI and BbsI, recognize asymmetric DNA sequences and cleave outside of their recognition sequences. Thus, the fragments and recipient vectors are designed to place the type IIS recognition sites distal to the cleavage sites, so that type IIS enzymes can remove the recognition sequences after assembly. The type IIS enzyme-based seamless assembly system offers at least three advantages. First, the overhang sequence created is not dictated by the restriction enzymes, and yet no footprint sequence is retained. Second, the overhangs contain fragment-specific sequences, allowing orderly assembly of multiple fragments in one reaction. Third, the restriction sites can be eliminated from the final assembled products.

In this study, we exploited the type IIS restriction endonuclease-based synthetic biology methodology and developed a fast assembly of multiplex siRNAs (FAMSi) system to silence gene expression in mammalian cells. Through a series of proof-of-concept experiments, we demonstrated that multiple fragments containing three, four, or five siRNAs targeting the common Smad4, and/or BMP receptor-spe-
cific Smad1, Smad5, and Smad8 required for BMP9 osteogenic signaling could be efficiently assembled. The constructed multiplex siRNAs effectively knocked down the expression of Smad4 and/or Smad1, Smad5, and Smad8 in mesenchymal stem cells (MSCs), and inhibited all aspects of BMP9-induced osteogenic differentiation in bone marrow mesenchymal stem cells (BMSCs) in vitro and in vivo. Thus, we demonstrate that the engineered FAMSi system provides a one-step fast-track platform to assemble multiplexed siRNAs in a single vector, and thus may be a valuable tool to interrogate gene function and/or to develop novel and efficacious siRNA-based therapeutics.

RESULTS

The FAMSi System Facilitates the Expression and Delivery of Multiplexed siRNAs

We have demonstrated that retroviral and adenovector-mediated expression of siRNAs driven by convergent U6 and H1 promoters effectively silences target gene expression in mammalian cells in vitro and in vivo.16,17,19,26,29 To develop the FAMSi system that enables rapid construction of multiple siRNA expression cassettes through an ordered multi-fragment assembly determined by ligating Watson-Crick base-paired overhangs, we took advantage of two commonly used type IIS restriction enzymes, BsaI and BbsI, both of which cut downstream random sequences and leave a 4-nt 5’ end protruding overhang (Figure 1A). The choice of these two enzymes should broaden the utility of this system, as either or both should be unique in most vectors or potential siRNA target sites.

The FAMSi system consists of three vectors, that is, two template vectors, pH1U6-T1 and pH1U6-T2, and the destination vector pSiEB. The pH1U6-T1 and pH1U6-T2 vectors contain the H1 and U6 promoters in a back-to-back configuration and are used as templates for Hi-Fi PCR amplification with siRNA sequence-containing primers (Figures S1 and S2). Alternatively, the retroviral vector pSiEB contains a built-in U6-H1 promoter unit flanking the unique BbsI-A and BbsI-R sites, which share unique but complementary overhangs to BsaI-A and BsaI-R, respectively (Figure S3).

The one-step assembly of multiplexed U6-H1-driven siRNA cassettes into pSiEB starts with simultaneous Hi-Fi PCR amplification of back-to-back H1-U6 fragments with primers containing siRNA sequences and unique BsaI sites. The PCR-amplified fragments are then digested with BsaI and subjected to a quick preassembly with T4 DNA ligase. The desired preassembled fragments are gel-purified and subcloned into the BbsI-digested pSiEB vector, followed by transformation of competent bacterial cells and colony PCR identification (Figure 1B).

Three siRNA Sites Targeting Mouse Smad4 Can Be Efficiently Assembled into pSiEB Using the FAMSi System

To carry out the proof-of-principle experiments on the technical and functional feasibility of the FAMSi system, we chose to construct a series of siRNA vectors that target the BMP9-dependent Smad signaling pathway, as we and others have demonstrated that Smad4 and BMP receptor-specific Smad1/Smad5/Smad8 play an important role in BMP9-induced osteoblastic differentiation of MSCs.30–38
To simplify the validation process, we started with the construction of a vector that expresses three siRNAs targeting mouse Smad4 or simSmad4 (Figure 2A, a). We demonstrated that the two siRNA-containing fragments (~0.5 kb each) were readily obtained through PCR amplification (Figure 2A, b). After BsaI digestion, these two fragments were effectively preassembled into a larger ~1-kb fragment and subcloned into BbsI-digested pSiEB (Figure 2A, c). For bacterial colony PCR screening, primers were designed based on the ordered siRNA cassettes using primer pairs to amplify the sequences between neighboring siRNA sequences (Figure 2B, a). Among 20 randomly picked bacterial colonies, 15 showed positive PCR screening results (Figure 2B, b), which was further confirmed by two pairs of PCR primers at the plasmid DNA level (Figure 2B, c). All the positive clones were also confirmed by restriction enzyme digestions and DNA sequencing reactions (data not shown). These constructs were pooled and designated as pSiEB-simSmad4 for further functional assays. Therefore, the above results demonstrate that the FAMSi system offers a highly efficient approach to the construction of three siRNA sites for any RNAi studies.

### Four and Five siRNA Sites Targeting Mouse Smad1/Smad4/Smad5/Smad8 Can Be Assembled into pSiEB in One Step Using the FAMSi System

An ideal versatile siRNA expression system should allow one to express more than three siRNAs in one vector in order to silence the expression of multiple genes of interest. Thus, we further tested how efficiently multiple siRNA sites could be effectively assembled into pSiEB with the FAMSi system. We first tested the feasibility of assembling four siRNAs that target mouse Smad1/Smad4/Smad5/Smad8, with one siRNA site for each Smad gene (Figure 3A, a). We found that the three fragments containing the four simSmad sites were effectively PCR amplified (~0.5 kb each) (Figure 3A, b). Furthermore, the three BsaI-digested fragments were readily preassembled into one large fragment of ~1.5 kb (Figure 3A, c), followed by subcloning into BbsI-digested pSiEB, yielding pSiEB-simSmad1458 (Figure 3A, d). From the bacterial colony screening, 4 of the 20 randomly picked colonies were PCR positive (Figure 3A, e), and the four positive clones were confirmed by three pairs of PCR primers.
primers (Figure 3A, f), which were further confirmed by restriction digestions and DNA sequencing (data not shown). These confirmed clones were pooled and designated as pSiEB-simSmad1458.

We then tested the feasibility and efficiency of assembling five siRNA sites using the FAMSi system by constructing five siRNAs that target mouse Smad4/Smad5/Smad8 (with two siRNA sites for Smad4 and one siRNA site each for the other three Smads) (Figure 3B, a). We found that the four fragments containing the five simSmad sites were effectively PCR amplified (~0.5 kb each) (Figure 3B, b).

The four BsaI-digested fragments were readily preassembled into a larger fragment of ~2.0 kb (Figure 3B, c), followed by subcloning into BbsI-digested pSiEB, yielding pSiEB-simSmad1458 (Figure 3B, d). It is noteworthy that a partially preassembled product of ~1.5 kb was also observed (Figure 3B, c), suggesting that the preassembly of more than four (including four) fragments may require a longer ligation time to ensure the full assembly. From the bacterial colony screening, 4 of the 20 randomly picked colonies were PCR positive (Figure 3B, e), and the four positive clones were confirmed by the four pairs of PCR primers (Figure 3B, f), which were further confirmed by restriction digestions and DNA sequencing (data not shown). These confirmed clones were pooled and designed as pSiEB-simSmad4158.

We also analyzed the assembly specificity of the PCR-amplified fragments. For the four-siRNA three-fragment assembly, we found that Frag1+2, Frag2+3, and Frag1+2+3 yielded the expected assembled product of ~1.5 kb, whereas no assembled product was found in...
the Frag1+3 assembly reaction (Figure 4A, a). Similarly, for the assembly of five-siRNA four fragments, we detected the presence of expected products assembled from the neighboring siRNA fragments, whereas no or very few products were observed in random assembly reactions (Figure 4A, b). It is noteworthy that intermediate products were detected in these assembly reactions, suggesting that longer ligation time may be required to ensure the full assembly (Figure 4A). Nonetheless, the specificity analysis indicated that the tested four and five siRNA-containing fragments with unique BsaI sites were assembled in the predesigned orderly fashion with high specificity. Taken together, the above results demonstrate that the one-step assembly of multiple siRNA sites using the FAMSi system is technically feasible with high efficiency.

**The FAMSi-Mediated Expression of simSmad Effectively Silences Smad Expression and Inhibits BMP9-Induced Osteoblastic Differentiation of MSCs**

We analyzed the silencing efficiency for the above multiplex siRNAs by establishing retrovirally transduced stable lines in the mouse MSC line BMSCs, resultant BMSC-simSmad4, BMSC-simSmad1458, and BMSC-simSmad4158, and the siControl line BMSCs. In BMSC-simSmad4 cells, touchdown quantitative real-time PCR analysis revealed that Smad4 expression significantly decreased to approximately 33% and 54% of that of BMSCs when infected with Ad-GFP and Ad-BMP9, respectively (Figure 4B). The silencing efficiency of the Smads was further confirmed by western blotting analysis with Smad4 and Smad1/5/8 antibodies (Figure S4).

In the BMSC-simSmad1458 cells infected with Ad-GFP (i.e., silencing efficiency of endogenous Smads), we found that the expression levels for Smad4, Smad1, Smad5, and Smad8 decreased to approximately 42%, 60%, 65%, and 37% of that of the Ad-GFP-infected BMSCs. Accordingly, in the BMSC-simSmad1458 cells infected with Ad-BMP9, the expression levels of the four Smad genes significantly decreased, compared with that of the Ad-BMP9-infected BMSCs (Figure 4C). In particular, simSmad1458 effectively blunted the BMP9-induced expression of BMPR-specific Smad1, Smad5, and Smad8 (Figure 4C). Similar results were obtained in Ad-GFP- and Ad-BMP9-infected BMSC-simSmad4158 cells when compared with the infected BMSCs (Figure 4D). Collectively, these results strongly demonstrated that FAMSi-mediated expression of multiplexed siRNAs that either target a single gene or multiple genes can accomplish profound silencing effects on target expression.

We further tested whether silencing Smad genes would impact BMP9-induced osteogenic signaling in MSCs. The three BMSC-simSmad lines, along with the control BMSCs, were infected with Ad-GFP or Ad-BMP9. The basal expression (i.e., GFP groups) of osteogenic regulators Runx2 and osteonectin (Oxn), as well as osteogenic markers Alp and osteopontin (Opn), was noticeably reduced in targeted cells, compared with that of the control BMSCs (Figure 5). More importantly, BMP9-induced expression of Runx2, Oxn, Alp, and Opn, which are known to be upregulated by BMP9,48–41 was significantly inhibited in the three BMSC-simSmad lines, compared with that of the control BMSC line (Figure 5). Furthermore, BMP9-induced Sox9 expression was also reduced in the three BMSC-simSmad lines, compared with that of the control BMSC line (Figure 5). Interestingly, silencing Smads in BMSCs significantly enhanced BMP9-induced expression of Ppara (Figure 5), suggesting that blockade of BMP9-induced osteogenic differentiation may be beneficial to adipogenic differentiation of MSCs.

Next, we assessed the effect of silencing Smads on BMP9-induced early osteogenic marker ALP activity. Histochemical staining assays revealed that, compared with the control BMSCs, BMP9-induced ALP activity staining was inhibited in the three BSMS-simSmad lines at days 3 and 7 after Ad-BMP9 infection (Figure 6A, a and b). The quantitative assays further demonstrated that BMP9-induced ALP activity was significantly inhibited in the three BMSC-simSmad lines at days 3, 5, and 7 after Ad-BMP9 infection, compared with that in the control BMSCs (Figure 6B). Furthermore, silencing Smads in MSCs significantly diminished the BMP9-induced in vitro matrix mineralization as revealed by alizarin red S staining (Figure 7A, a and b). On the contrary, knockdown of Smad expression in MSCs enhanced BMP9-induced adipogenic differentiation as indicated by oil red O staining (Figure 7B, a and b), suggesting that BMP9 may induce adipogenic differentiation at least in part through a Smad-independent mechanism. Lastly, we analyzed the effect of silencing Smads on BMP9-induced ectopic bone formation capability and found that silencing Smad4 and/or Smad1/5/8 significantly diminished the sizes and volumetric measures of the ectopic bone masses in athymic nude mice (Figures 8A–8C). Histological analysis further indicated that, compared to that of the control BMSC group, silencing Smad expression effectively decreased BMP9-induced trabecular bone formation (Figure 8D). Trichrome staining also demonstrated that more immature bone or unmineralized bone matrix was detected in the three simSmad lines (Figure 8E).
Nonetheless, it is noteworthy that the decrease in BMP9-induced ALP activity, in vitro matrix mineralization, and ectopic bone formation in MSCs were not statistically different among the three simSmad lines, suggesting that the FAMSi-mediated expression of three siRNAs targeting Smad4 expression alone (i.e., BMSC-simSmad4) may exert similar biological effects on BMP9-induced osteogenic signaling in MSCs, compared to the two lines expressing siRNAs targeting Smad1, Smad5, and Smad8, in addition to Smad4 (i.e., BMSC-simSmad1458 and BMSC-simSmad41258).

**DISCUSSION**

By exploiting the type IIS restriction endonuclease-based synthetic biology approach, we have developed the simple, efficient, and user-friendly FAMSi technology for the rapid assembly of multiplex siRNA expression cassettes. In our proof-of-principle experiments, we demonstrated that fragments containing three, four, or five siRNA sites targeting the BMP9/Smad signaling pathway could be efficiently assembled, and their gene expression silencing efficacy was fully validated by a series of in vitro and in vivo biological functional assays in MSCs. Therefore, the engineered FAMSi system may be a valuable tool to explore siRNA biology.

During the process of developing and optimizing the FAMSi system, we learned several important technical considerations. First, while it is theoretically feasible to bypass the preassembly step of all desirable fragments, we found practically that a direct shotgun approach by pooling all digested fragments and destination vector yielded 5- to 10-fold lower cloning efficiency. Second, we performed gel purifications of PCR-amplified and BsaI-digested fragments and achieved high assembly efficiency, while the unpurified fragments decreased the assembly efficiency by approximately 6-fold. Third, it is important to use the neighboring siRNA sequences as PCR primer pairs to perform bacterial colony PCR screening due to the repeated U6 and H1 promoter sequences. Otherwise, tandem or laddered products lead to inconclusive screening results. Lastly, while we only designed up to five siRNA cassettes in this proof-of-concept study, it is conceivable that the FAMSi system could accommodate more than five siRNA sites, as long as unique sequences of the 5’ end overhang of

![Figure 4. Seamless and Orderly Assembly of Multiplex siRNA Fragments and Functional Characterization of the Multiplex siRNA Expression Vectors](image-url)
BsaI are used and validated. Therefore, the FAMSi system is highly versatile and flexible in this regard. Furthermore, it is noteworthy that the current FAMSi system can be easily reconfigured and expressed in different viral vector systems, such as adenoviral vectors, adenovirus-associated viral vectors, lentiviral vectors, and HSV vectors, to name a few.

Numerous efforts have been devoted to the development of effective construction and/or delivery systems for multiple siRNAs. In one of our early efforts, we developed the pSOS vector system, in which a single siRNA is produced by convergent U6 and H1 promoters. In order to accommodate the expression of multiple siRNA cassettes in a single vector, we later developed a one-step pSOK system by exploiting the

Figure 5. The Smad-Targeting siRNAs Effectively Inhibit BMP9-Stimulated Osteogenic Markers in BMSCs

The BMSCs stably expressing simSmad4, simSmad1458, simSmad4158 or siControl cells (i.e., BMSCs) were infected with AdGFP or AdBMP9 for 48 h. Total RNA was isolated and subjected to touchdown quantitative real-time PCR using primers specific for mouse Runx2, Osx, Alp, Opn, Sox9, and Pparγ (Gapdh as the reference gene). *p < 0.05, **p < 0.01, compared with that of the siControl counterpart (BMSCs).
use of the Gibson DNA assembly technology. However, the Gibson DNA assembly methodology is finicky and empirical. More recently, we developed the BSG restriction enzyme-based two-stage system to express three siRNA sites. While we and others have successfully used these vector systems to accomplish siRNA-mediated gene silencing, these above systems are not user-friendly and require prospective users to possess significant experience in molecular cloning. In this study, we developed a simple and more user-friendly FAMSi system to accomplish the expression of multiple siRNAs in mammalian cells. It is noteworthy that the FAMSi system can be easily adapted to express multiple single guide RNAs (sgRNAs) for CRISPR-Cas9-based genome-editing investigation.
Several other strategies for single vector-based multiple siRNA and/or sgRNA expression have also been reported. Similar to our pSOK system, the string assembly guide RNA (gRNA) cloning (STAgR) technique involves a single-step multiplexing of gRNAs by using the N20 targeting sequences as necessary homologies for Gibson assembly. The adaptable system for assembly of multiplexed plasmids (ASAP) methodology allows the assembly of multiple gRNA cassettes via the “PCR-on-ligation” process. However, it is technically challenging to modify these systems for siRNA expression, as siRNAs necessitate the expression of both strands, which is not required for sgRNA expression.

In summary, we exploited the type IIS restriction endonuclease-based synthetic biology approach and developed the efficient and user-friendly FAMSi technology for the rapid assembly of multiplex siRNA expression cassettes. In a series of proof-of-concept experiments, we demonstrated that multiple fragments containing three, four, or five siRNA sites targeting the common Smad4 and/or Smad1, Smad5, and Smad8 required for the BMP9/Smad signaling pathway could be efficiently assembled. The constructed multiplex siRNAs were shown to effectively knock down the expression of Smad4 and/or Smad1, Smad5, and Smad8 in MSCs, and to inhibit all aspects of BMP9-induced osteogenic differentiation in MSCs, including the decreased expression of osteogenic regulators and markers, a reduced ALP activity, and diminished in vitro matrix mineralization and in vivo ectopic bone formation. Collectively, our findings demonstrate that the engineered FAMSi system provides a one-step fast-track technology to express multiplexed siRNAs in a single vector, and thus it should be a valuable tool to investigate gene functions and/or to develop innovative siRNA-based therapeutics.

MATERIALS AND METHODS

Cell Culture and Chemicals

The mouse MSC line imBMSCs (referred to as BMSCs hereafter) is conditionally immortalized mouse BMSCs as previously described. The 293pTP and RAPA cells were previously characterized HEK293 derivative cells. Restriction endonucleases, NEBniIlder HiFi DNA assembly master mix, Phusion high-fidelity DNA polymerase, and the electrocompetent DH10B cells were purchased from New England Biolabs (NEB, Ipswich, MA, USA). Blasticidin S was ordered from InvivoGen (San Diego, CA, USA). Unless indicated otherwise, other chemicals/reagents were purchased from Thermo Fisher Scientific (Waltham, MA, USA) or Sigma-Aldrich (St. Louis, MO, USA).
Development of the FAMSi Vectors

The FAMSi system consists of three vectors, two template vectors (pH1U6-T1 and pH1U6-T2) and a destination vector (pSiEB). Both template vectors were constructed on the base of our homemade pMOLuc and pMOK vectors by incorporating the back-to-back human H1 and U6 promoters. The pH1U6-T1 and pH1U6-T2 vectors have a slight sequence difference at the 3' end of the H1 promoter region. The pH1U6-T1 vector is used for the amplification of the first fragment, while the pH1U6-T2 vector is used for amplifying all other fragments. The full-length sequences and vector maps for pH1U6-T1 and pH1U6-T2 are shown in Figures S1 and S2.

The destination vector pSiEB was constructed through a series of subcloning experiments on the base of our previously reported retroviral siRNA expression systems, such as the pSEB vector, which has been used to express single siRNA driven by convergent U6 and H1 promoters.

The destination vector pSiEB was constructed through a series of subcloning experiments on the base of our previously reported retroviral siRNA expression systems, such as the pSEB vector, which has been used to express single siRNA driven by convergent U6 and H1 promoters. The BbsI site in the blasticidin S coding region was first silently mutated through the Gibson assembly approach by following the manufacturer’s instructions. Then, a long oligonucleotide cassette containing both BbsI-A and BbsI-R sites was inserted between the convergent U6 and H1 promoters through Gibson assembly. The full-length sequence and vector map for pSiEB are shown in Figure S3. All cloning junctions and inserted oligonucleotide fragments were DNA sequencing verified. Details about the vector construction are available upon request.

**Table 1**

| siRNA Site       | Primer (5' → 3')          |
|------------------|---------------------------|
| siControl        | Forward: CTCGAGGCGCTCGTCCGCTCTTTCTGCACTGCTGCTTGAGGAGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTA

**Figure 6. Silencing Mouse Smads Effectively Inhibits BMP9-Induced Osteogenic Differentiation of BMSCs**

The BMSCs stably expressing simSmad4, simSmad1458, simSmad4158, or siControl cells (BMSCs) were infected with AdGFP or AdBMP9 for 36 h and collected for subcutaneous injection into the flanks of athymic nude mice (n = 5 per group). At 4 weeks after implantation, animals were sacrificed, and bony masses at the injection sites were retrieved. (A) Representative gross images are shown. No detectable masses were retrieved from the GFP group. (B) The retrieved masses were subjected to µCT imaging, and representative results of the 3D reconstruction of scanning are shown. (C) The average bone volumes of the retrieved bony masses were quantitatively analyzed by using Amira software. **p < 0.01, simSmad groups versus the BMSC group.** (D and E) The retrieved samples were further decalcified and subjected to hematoxylin and eosin staining (D) and Masson’s trichrome staining (E). Representative images are shown.

**Establishment of BMSC Stable Lines Expressing siRNAs Targeting Smads**

The retroviral vector-mediated transduction and establishment of stable cell lines were carried out as previously described. Briefly, the retroviral transfer vectors pSiEB-simSmad4, pSiEB-simSmad1458, and pSiEB-simSmad4158 were co-transfected with pCL-Ampho into subconfluent 293 Phoenix Ampho (293PA) cells to package retroviruses. The retrovirus-containing supernatants were harvested at 36–72 h after transfection and pooled to infect subconfluent BMSCs. At 48 h post-infection, the cells were subjected to blastidicin S selection (5 μg/mL). The resulting stable lines were designated as BMSC-simSmad4, BMSC-simSmad1458, and BMSC-simSmad4158. The previously constructed pSEB-siControl was used to establish a stable control line, designated as BMSCs. All stable lines were kept in LN2 tanks for future use.

**Construction and Amplification of Recombinant Adenoviral Vectors Ad-BMP9 and Ad-GFP**

Recombinant adenoviruses were created by using the AdEasy technology as reported. Briefly, the coding region of human
BMP9 was PCR amplified and subcloned into an adenoviral shuttle vector to generate the recombinant adenoviral vector pAd-BMP9, which was then used to produce and/or amplify the adenovirus Ad-BMP9 in 293FT or RAPA cells. Ad-BMP9 was also co-expressed GFP as reported. The Ad-GFP was used as a mock virus control. Polybrene (4–8 µg/mL) was added to all adenoviral infections to enhance viral transduction efficiency as reported.

RNA Isolation and Touchdown Quantitative Real-Time PCR
Total RNA was purified by using the NucleoZOL RNA isolation kit (Takara Bio USA, Mountain View, CA, USA) and subjected to reverse transcriptase (RT) reactions using hexamer and Moloney murine leukemia virus (M-MuLV) RT (NEB). The resultant RT cDNA products were properly diluted and used as touchdown quantitative real-time PCR templates. Touchdown quantitative real-time PCR primers were designed with the Primer3 Plus program. Touchdown quantitative real-time PCR reactions were carried out as described. Brieﬂy, the SYBR Green (Bimake, Houston, TX, USA) qPCR reactions were carried out by using the following cycling program: 95°C for 3 min for 1 cycle; 95°C for 20 s, 66°C for 10 s per cycle, and then –3°C per cycle for four cycles; followed by 95°C for 10 s, 55°C for 15 s, and 70°C for 1 s for 40 cycles. Gapdh was used as a reference gene. The gene expression calculations were performed using the 2–ΔΔCT method. Touchdown quantitative real-time PCR primer sequences are listed in Table S1.

ALP Assays
ALP activities were assessed both qualitatively and quantitatively by using histochemical staining and a modiﬁed Great EscAPe secreted alkaline phosphatase (SEAP) chemiluminescence assay (Takara Bio USA), respectively, as described. Each assay condition was done in triplicate.

Matrix Mineralization Assay (Alizarin Red S Staining)
The cells were infected with Ad-BMP9 or Ad-GFP and cultured with 10% FBS DMEM containing ascorbic acid (50 mg/mL) and β-glycerophosphate (10 mM) for the indicated time periods. Alizarin red S staining was carried out to assess mineralized matrix nodules as described. The staining of calcium mineral deposits was documented under a bright ﬁeld microscope. For quantitative assays, the alizarin red stained was dissolved in 10% acetic acid, and the absorbance was measured photometrically at 405 nm. Each assay was done in triplicate.

Oil Red O Staining Assay
Subconfluent BMSCs were infected with indicated adenoviruses for 7 or 14 days. Oil red O staining was carried out as described. Brieﬂy, the cells were ﬁxed with 10% formalin at room temperature for 10 min and washed with PBS. After residual PBS being aspirated, the cells were stained with oil red O solution, placed in a 37°C incubator for 1 h, and washed with tap water. The stained lipid droplets were documented under a bright ﬁeld microscope. For quantitative assays, the oil red O stain was eluted in 2-propanol and the absorbance was measured photometrically at 510 nm. Each assay was done in triplicate.

Subcutaneous Stem Cell Implantation and Ectopic Bone Formation
The use and care of athymic nude mice were approved by the Institutional Animal Care and Use Committee. All experimental procedures were carried out according to the approved guidelines. The subcutaneous stem cell implantation procedure was carried out as previously described. Brieﬂy, subconfluent BMSCs were co-infected with Ad-BMP9 or Ad-GFP for 36 h and then collected, resuspended in PBS (~50 µL per injection), and subcutaneously injected into the flanks of nude mice (Envigo/Harlan Laboratories; n = 5/group, female, 5 weeks old; 2 × 10^6 cells per injection). At the indicated endpoints, nude mice were sacriﬁced and the masses were retrieved for microcomputed tomography (µCT) imaging and histologic evaluation as described.

µCT Analysis
The retrieved masses were ﬁxed in 10% formalin and imaged using the X-CUBE (Molecubes, Gent, Belgium) at the Integrated Small Animal Imaging Research Resource (iSAIRR) of The University of Chicago. Spiral high-resolution CT acquisitions were performed with an X-ray source of 50 kVp and 200 µA. Volumetric CT images were reconstructed in a 350 × 350 × 840 format with voxel dimensions of 200 µm^3. All image data were analyzed by Amira 5.3 (Visage Imaging), and 3D volumetric data and bone density were calculated as described.

Hematoxylin and Eosin (H&E) and Masson’s Trichrome Staining
After µCT imaging, the ﬁxed samples were decalcified, parafﬁn-embedded, and subjected to serial sections and H&E staining and Masson’s trichrome staining as described.

Statistical Analysis
All quantitative experiments were carried out in triplicate and/or repeated in three independent batches. Data are expressed as mean ± standard deviation (SD). Statistical signiﬁcance was analyzed by using the one-way analysis of variance. p < 0.05 was considered statistically signiﬁcant.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.omtn.2020.10.007.

AUTHOR CONTRIBUTIONS
J.F., F.H., H.G., and T.–C.H. conceived and designed the study. F.H., N.N., Z.Z., D.W., A.J.L., B.L., A.F.L., and K.Q. performed the experiments and collected data. Y.F., E.W., X. Wang, X. Wu, H.L., J.Z., M.Z., Y.M., M.P., W.W., Y.Z., C.N., H.W., L.H., D.S., Q.L., X.Z., and K.F. participated in molecular cloning experiments, provided essential experimental materials, assisted in histological preparations, and provided qPCR data analysis and interpretations. T.–C.H., J.F., F.H.,
REFERENCES

1. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806–811.

2. Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J. (2000). An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404, 293–296.

3. Bobbin, M.L., and Rossi, J.J. (2016). RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu. Rev. Pharmacol. Toxcol. 56, 103–122.

4. Castell, S.E., and Martienssen, R.A. (2013). RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond. Nat. Rev. Genet. 14, 100–112.

5. Setten, R.L., Rossi, J.J., and Han, S.P. (2019). The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 18, 421–446.

6. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498.

7. Caplen, N.J., Parrish, S., Imani, F., Fire, A., and Morgan, R.A. (2001). Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98, 9742–9747.

8. Weng, Y., Xiao, H., Zhang, J., Liang, X.J., and Huang, Y. (2019). RNAi therapeutic and its innovative biotechnological evolution. Biotechnol. Adv. 37, 801–825.

9. Whitehead, K.A., Langer, R., and Anderson, D.G. (2009). Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129–138.

10. Czech, M.P., Aouadi, M., and Tez, G.J. (2011). RNAi-based therapeutic strategies for metabolic disease. Nat. Rev. Endocrinol. 7, 473–484.

11. Pecot, C.V., Calin, G.A., Coleman, R.L., Lopez-Berestein, G., and Sood, A.K. (2011). RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11, 59–67.

12. Fellmann, C., and Lowe, S.W. (2014). Stable RNA interference rules for silencing. Nat. Cell Biol. 16, 10–18.

13. Iorns, E., Lord, C.J., Turner, N., and Ashworth, A. (2007). Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 6, 556–568.

14. Kim, D.H., and Rossi, J.J. (2007). Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173–184.

15. de Fougerolles, A., Vornlocher, H.P., Maraganeore, J., and Lieberman, I. (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443–453.

16. Luo, Q., Kang, Q., Song, W.X., Luu, H.H., Luo, X., An, N., Luo, J., Deng, Z.L., Jiang, W., Yin, H., et al. (2007). Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing. Gene 395, 160–169.

17. Deng, F., Chen, X., Liao, Z., Yan, Z., Wang, D., Deng, Y., Zhang, Q., Zhang, Z., Ye, J., Qiao, M., et al. (2014). A simplified and versatile system for the simultaneous expression of multiple siRNAs in mammalian cells using Gibson DNA assembly. PLoS ONE 9, e113064.

18. Huang, X., Wang, F., Zhao, C., Yang, S., Cheng, Q., Tang, Y., Zhang, F., Zhang, Y., Luo, W., Wang, C., et al. (2019). Dendrimers and tooth-alveolar bone complex defects in BMP9/GDF2 knockout mice. Stem Cells Dev. 28, 683–694.

19. Yan, S., Zhang, R., Wu, K., Cui, J., Huang, S., Ji, X., An, L., Yuan, C., Gong, C., Zhang, L., et al. (2018). Characterization of the essential role of bone morphogenetic protein 9 (BMP9) in osteogenic differentiation of mesenchymal stem cells (MSCs) through RNA interference. Genes Dis. 5, 172–184.

20. Liao, J., Wei, Q., Zou, Y., Fan, J., Song, D., Cui, J., Zhang, W., Zhu, Y., Ma, C., Hu, X., et al. (2017). Notch signaling augments BMP9-induced bone formation by promoting the osteogenesis-angiogenesis coupling process in mesenchymal stem cells (MSCs). Cell. Physiol. Biochem. 41, 1905–1923.

21. Liao, J., Yu, X., Hu, X., Fan, J., Wang, J., Zhang, Z., Zhao, C., Zeng, Z., Shu, Y., Zhang, R., et al. (2017). IncRNA H19 mediates BMP9-induced osteogenic differentiation of mesenchymal stem cells (MSCs) through Notch signaling. Oncotarget 8, 53581–53601.

22. Wang, J., Liao, J., Zhang, F., Song, D., Lu, M., Liu, H., Fan, J., et al. (2017). NEL-like molecule-1 (Nell1) is regulated by bone morphogenetic protein 9 (BMP9) and potentiates BMP9-induced osteogenic differentiation at the expense of adipogenesis in mesenchymal stem cells. Cell. Physiol. Biochem. 41, 484–500.

23. Deng, Y., Wang, Z., Zhang, F., Qiao, M., Yan, Z., Wei, Q., Wang, J., Liu, H., Fan, J., Zou, Y., et al. (2016). A blockade of IGF signaling sensitizes human ovarian cancer cells to the antihelminthic niclosamide-induced anti-proliferative and antiancier activa-

24. Zhang, H., Wang, J., Deng, F., Huang, E., Yan, Z., Wang, Z., Deng, Y., Zhang, Q., Zhang, Z., Ye, J., et al. (2015). Canonical Wnt signaling acts synergistically on BMP9-induced osteoid/odontoblastic differentiation of stem cells of dental apical papilla (SCAPs). Biomaterials 39, 145–154.

25. Luu, H.H., Song, W.X., Luo, X., Manning, D., Luo, J., Deng, Z.L., Sharff, K.A., Montag, A.G., Haydon, R.C., and He, T.C. (2007). Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J. Orthop. Res. 25, 665–677.
31. Wang, R.N., Green, J., Wang, Z., Deng, Y., Qiao, M., Peabody, M., Zhang, Q., Ye, J., Yan, Z., Dendurili, S., et al. (2014). Bone morphogenetic protein (BMP) signaling in development and human diseases. Genes Dis. 1, 87–105.

32. Zhang, F., Song, J., Zhang, H., Huang, E., Song, D., Tollef, V., Wang, J., Wang, J., Mohammed, M., Wei, Q., et al. (2016). Wnt and BMP signaling crosstalk in regulating dental stem cells: implications in dental tissue engineering. Genes Dis. 3, 263–276.

33. Pakvasa, M., Harvaz, P., Boachie-Mensah, M., Jones, A., Coalson, E., Liao, J., Zeng, Z., Wu, D., Qin, K., Xu, X., et al. (2020). Notch signaling: its essential roles in bone and craniofacial development. Genes Dis. Published online April 11, 2020. https://doi.org/10.1016/j.gendis.2020.04.006.

34. Luther, G., Wagner, E.R., Zhu, G., Kang, Q., Luo, Q., Lamplot, J., Bi, Y., Luo, X., Luo, J., Teven, C., et al. (2011). BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential. Curr. Gene Ther. 11, 229–240.

35. Doudna, J.A., and Charpentier, E. (2014). Genome editing. The new frontier of therapeutic medicine. Genes Dis. 2, 332–341.

36. Zhang, L., Luo, Q., Shu, Y., Zeng, Z., Huang, S., Ji, X., Yuan, C., Zhang, L., Liu, W., Huang, B., Feng, Y., et al. (2018). A simplified system to express customizable inhibitors of miRNA for stable and potent suppression of miRNA functions. Mol. Ther. Nucleic Acids 13, 556–567.

37. Liu, W., Deng, Z., Zeng, Z., Fan, J., Feng, Y., Wang, X., Cao, D., Zhang, B., Yang, L., Liu, B., et al. (2019). Highly expressed BMP-9/GDF2 in postnatal mouse liver and lungs may account for its pleiotropic effects on stem cell differentiation, angiogenesis, tumor growth and metabolism. Genes Dis. 7, 235–244.

38. Mostafa, S., Pakvasa, M., Coalson, E., Zou, A., Alvery, A., Castill,io, H., Fan, J., Li, A., Feng, Y., Wu, D., et al. (2019). The wonders of BMP9: from mesenchymal stem cell differentiation, angiogenesis, neurogenesis, tumorigenesis, and metabolism to regenerative medicine. Genes Dis. 6, 201–223.

39. Feng, Y., Kang, Q., Cheng, H., Li, X., Sun, M.H., Jiang, W., Luo, H.H., Park, J.Y., Haydon, R.C., and He, T.C. (2003). Transcriptional characterization of bone morphogenetic proteins (BMPs)-mediated osteogenic signaling. I. Cell. Biochem. 90, 1149–1165.

40. Peng, Y., Kang, Q., Luo, Q., Jiang, W., Si, W., Liu, B.A., Liu, H.H., Park, J.K., Li, X., Luo, J., et al. (2004). Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J. Biol. Chem. 279, 32941–32949.

41. Zhang, L., Luo, Q., Shu, Y., Zeng, Z., Huang, B., Feng, Y., Zhang, B., Wang, X., Lei, Y., Ye, Z., et al. (2019). Transcriptomic landscape regulated by the 14 types of bone morphogenetic proteins (BMPs) in lineage commitment and differentiation of mesenchymal stem cells (MSCs). Genes Dis. 6, 258–275.

42. Si, W., Kang, Q., Luo, H.H., Park, J.K., Luo, Q., Song, W.X., Jiang, W., Luo, X., Li, X., Yin, H., et al. (2006). CCN1/Cyr61 is regulated by the canonical Wnt signal and plays a role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol. Cell. Biol. 26, 2955–2964.

43. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823.

44. Dominguez, A.A., Lim, W.A., and Qi, L.S. (2016). Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat. Rev. Mol. Cell Biol. 17, 5–15.

45. Doudna, J.A., and Charpentier, E. (2014). Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096.

46. Wang, H., La Russa, M., and Qi, L.S. (2016). CRISPR-Cas9 in genome editing and beyond. Annu. Rev. Biochem. 85, 227–264.

47. Breuning, C.T., Durovic, T., Neuner, A.M., Baumann, V., Wiesbeck, M.F., Kofler, A., Gotz, M., Ninkovic, J., and Stricker, S.H. (2018). One step to customizable gRNA vectors for multiplex CRISPR approaches through string assembly gRNA cloning (STAgR). PLoS ONE 13, e0196015.

48. Zuckermann, M., Hvitmyr, J., Yaxdaranparast, H., Zapatka, M., Jones, D.T.W., Lichter, P., and Gronych, J. (2018). A novel cloning strategy for one-step assembly of multiplex CRISPR vectors. Sci. Rep. 8, 17499.
